

## CLAIMS

1. A blood ammonia lowering agent containing xylobiose as an active ingredient.
2. The blood ammonia lowering agent according to claim 1, which contains xylooligosaccharide containing xylobiose as a main ingredient.
3. The blood ammonia lowering agent according to claim 2, wherein said xylooligosaccharide contains at least 30% of xylobiose.
4. The blood ammonia lowering agent according to any one of claims 1 - 3, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.
5. A therapeutic agent of hyperammonemia containing xylobiose as an active ingredient.
6. The therapeutic agent of hyperammonemia according to claim 5, which contains xylooligosaccharide containing xylobiose as a main ingredient.
7. The therapeutic agent of hyperammonemia according to claim 6, wherein said xylooligosaccharide contains at least 30% of xylobiose.
8. The therapeutic agent of hyperammonemia according to any one of claims 5 - 7, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.
9. A therapeutic agent of hepatic encephalopathy containing xylobiose as an active ingredient.
10. The therapeutic agent of hepatic encephalopathy

according to claim 9, which contains xylooligosaccharide containing xylobiose as a main ingredient.

11. The therapeutic agent of hepatic encephalopathy according to claim 10, wherein said xylooligosaccharide contains at least 30% of xylobiose.

12. The therapeutic agent of hepatic encephalopathy according to any one of claims 9 - 11, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

13. Use of xylobiose for producing a blood ammonia lowering agent.

14. Use of xylooligosaccharide containing xylobiose as a main ingredient for producing a blood ammonia lowering agent.

15. Use of xylobiose for producing a therapeutic agent of hyperammonemia.

16. Use of xylooligosaccharide containing xylobiose as a main ingredient for producing a therapeutic agent of hyperammonemia.

17. Use of xylobiose for producing a therapeutic agent of hepatic encephalopathy.

18. Use of xylooligosaccharide containing xylobiose as a main ingredient for producing a therapeutic agent of hepatic encephalopathy.